Form 4: Protara Therapeutics Director Richard S. Levy Acquires Stock Options

Sentiment:

SEC Form 4


Director Richard S. Levy acquired stock options for 10,000 shares of Protara Therapeutics, Inc. on June 7, 2024.

Summary

  • On June 7, 2024, Richard S. Levy, a director of Protara Therapeutics, Inc., acquired stock options for 10,000 shares.
  • The exercise price of these options is $2.67.
  • The options vest in equal monthly installments over 12 months, with full vesting upon the company's next annual stockholder meeting or a change of control, contingent on continuous service on the Board.
  • Following the transaction, Levy directly owns 10,000 derivative securities.

Sentiment

Score: 5

Explanation: This is a routine disclosure of stock option grants, neither particularly positive nor negative.

Industry Context

This is a standard disclosure related to insider transactions, common in publicly traded companies.

Stakeholder Impact

  • The transaction could have a minor positive impact on shareholder confidence due to insider alignment.

Key Dates

DateDescription
06/07/2024Date of stock option acquisition
06/06/2034Expiration date of the stock options
06/10/2024Date of Form 4 filing

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.